GlassScriptPhysician profile
Dana M Johnson
NPI 1619289915
$2,818.82
in general payments reported to CMS, 2019-2025
21 companies · $72.29 in 2025
The $72.29 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $829 · 2023: $271 · 2024: $887 · 2025: $72.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.05 | 2021-2024 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $170.07 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $138.57 | 2021-2024 | Dificid |
| Novo Nordisk INC | $122.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $110.97 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $110.00 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $102.80 | 2024-2025 | Vowst |
| Evoke Pharma, INC. | $66.47 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $53.23 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $45.28 | 2023-2024 | Entyvio |
| Celgene Corporation | $30.21 | 2022 | |
| Lilly USA, LLC | $30.12 | 2023-2024 | Omvoh |
| Gilead Sciences, INC. | $26.17 | 2023 | |
| Braintree Laboratories, INC. | $25.28 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.01 | 2024 | |
| Pfizer INC. | $23.42 | 2022 | |
| Intercept Pharmaceuticals, INC. | $16.95 | 2021 | |
| Daiichi Sankyo INC. | $14.95 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.84 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.